ClinicalTrials.gg
CompletedNCT07131657Updated Jan 12, 2026

Ropiclobet for Regional Anesthesia and Post-Operative Pain Control in Upper Extremity Surgery

A Phase 2 interventional study of Ropivacaine + Clonidine + Betamethasone and Ropivacaine + Clonidine + Betamethasone in Nerve Block and Upper Extremity Surgery, sponsored by PHARMAFINA. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by PHARMAFINA · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a national, single-center, single-arm, open-label Phase II clinical trial designed to evaluate the efficacy and safety of Ropiclobet, a fixed-dose injectable solution containing Ropivacaine HCl, Betamethasone Sodium Phosphate, and Clonidine HCl.

The study includes three non-randomized dose groups and will enroll a total of 60 adult volunteers undergoing upper extremity surgery (arm, elbow, forearm, or hand). All participants will receive a single administration of Ropiclobet via supraclavicular brachial plexus block (SCB) under ultrasound guidance. Sedation may be provided if necessary; however, participants requiring general anesthesia will be excluded from the study.

Postoperatively, volunteers will be monitored in the PACU for 2 hours, followed by transfer to a regular hospital ward under anesthesiology supervision. All participants will remain under clinical observation for 48 hours following the procedure. If the sensory or motor block persists beyond this period, monitoring will continue until full resolution and an additional 6 hours of observation will be provided. Follow-up visits are scheduled for Day 15 and Day 30 post-procedure.

The primary efficacy endpoint is the duration of analgesia and the primary safety endpoint is the incidence and characterization of all adverse events occurring during the procedure and within 30 days postoperatively.

Read the detailed description

This national, single-center, single-arm, open-label Phase II clinical trial includes three dose groups and aims to evaluate the efficacy and safety of Ropiclobet. Ropiclobet Injectable Solution is a fixed-dose combination containing Ropivacaine HCl, Betamethasone Sodium Phosphate, and Clonidine HCl at concentrations of 5.0/0.4*/0.015 mg/mL (*the 10 mL ampoule contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone).

A total of 60 volunteers (Hospitalized patients in the orthopedic department or outpatients who are scheduled for surgery) undergoing upper extremity surgery (including arm, elbow, forearm, and hand surgeries) will receive a single administration of the Ropiclobet combination via supraclavicular brachial nerve blockade (SCB) under ultrasound guidance.

The study will include three dose groups:

  • Group I: 10 mL Ropiclobet combination (1 ampoule) diluted with 10 mL of 0.9% isotonic saline
  • Group II: 15 mL Ropiclobet combination (1.5 ampoules) diluted with 5 mL of 0.9% isotonic saline
  • Group III: 20 mL Ropiclobet combination (2 ampoules), administered undiluted. There will be no randomization for dose groups. The first 20 participants will be assigned to Group I. The study team will assess safety and efficacy parameters in these participants. Following the completion of 20 participants in Group I, the study will proceed to Group II. Group III will follow in the same manner, with 20 participants planned per group.

Ropiclobet injection will be performed preoperatively under sterile conditions by an experienced anesthesiologist. Only sedation may be administered if needed, and volunteers requiring general anesthesia will be withdrawn from the study.

Standard monitoring will include ECG, non-invasive blood pressure measurement, and pulse oximetry. Postoperatively, volunteers will be monitored in the PACU for 2 hours, followed by observation in the hospital ward under an anesthesiologist's supervision. Volunteers will remain under clinical observation for 48 hours post-procedure. If motor or sensory blockade persists beyond this period, monitoring will continue until full resolution plus an additional 6 hours. Follow-up visits will be at Day 15 and Day 30.

02

Conditions studied

  • Nerve Block
  • Upper Extremity Surgery

Keywords

  • ropivacaine
  • clonidine
  • betamethasone
  • supraclavicular brachial nerve block
03

In context

Lead sponsor

PHARMAFINA is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients with age of ≥18 years and ≤ 65 years at the time of consent.
  • Ability and willingness to provide or consent from their legal representative and willingness to comply with all planned visits and study procedures.
  • (ASA) physical status class of I-III
  • ≤ 30 kg/m2
  • An within normal values or clinically insignificant findings.
  • Patients undergoing upper extremity procedures suitable for SCB anesthesia, including arm, elbow, forearm, and hand surgeries.
  • Emergency and/or elective surgeries
  • Women of (WOCBP) must have a negative urine pregnancy testing at screening visit.

Exclusion criteria

Exclusion Criteria:

  • An inability to cooperate during the block placement.
  • Patients undergoing shoulder procedures.
  • History of allergy to active ingredients (including their derivatives) of the study medication.
  • History of allergy to analgesics (e.g. acetaminophen, non-steroidal anti-inflammatory medications, oral opioid analgesics)
  • History of shoulder or clavicular surgery.
  • Known bronchopulmonary or phrenic pathology compromising respiratory function.
  • Existing chronic pain disorders or history of use of ≥ 30mg oxycodone or equivalent per day
  • Pre-existing neurological deficits or peripheral neuropathy involving the operative upper extremity
  • Infection at the puncture site for the block.
  • History of coagulopathy disorders and/or bleeding diathesis.
  • Pregnant or breastfeeding.
  • History of any documented medical condition considered to be and could potentially affect patient safety or study outcome, in the opinion of the investigator: uncontrolled diabetes, uncontrolled hypertension, cardiovascular diseases, acute or chronic kidney diseases, liver diseases, psychiatric disorders, , systemic infection.
  • Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening which, in the opinion of the investigator, may put the patient at risk because of his/her participation in the study, or might influence the results of the study, or the patient's ability to complete the entire duration of the study.
  • Participation in a clinical trial involving current or another product in the previous 3 months.
  • Currently taking long-term systemic (excluding inhaled medication for asthma treatment)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Nerve block arm

    Volunteers will undergo supraclavicular brachial nerve block preoperatively using the combination drug Ropiclobet (Ropivacaine-Clonidine-Betamethasone)

    Drug: Ropivacaine + Clonidine + Betamethasone

Interventions

  • DrugRopivacaine + Clonidine + Betamethasone

    Drug pages: Ropivacaine · Clonidine · Betamethasone

    Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone) Group I: A total of 20 mL will be injected: 10 mL Ropiclobet (1 ampoule) + 10 mL of 0.9% isotonic saline

  • DrugRopivacaine + Clonidine + Betamethasone

    Drug pages: Ropivacaine · Clonidine · Betamethasone

    Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone) Group II: A total of 20 mL will be injected: 15 mL Ropiclobet (1.5 ampoules) + 5 mL of 0.9% isotonic saline

  • DrugRopivacaine + Clonidine + Betamethasone

    Drug pages: Ropivacaine · Clonidine · Betamethasone

    Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone) Group III: A total of 20 mL will be injected: 20 mL Ropiclobet (2 ampoules)

06

What researchers measure

Primary outcomes

  1. Duration of analgesia

    Time frame: From end of Ropiclobet injection to the first sensation of pain at surgical site (minutes/hours), up to 48 hours

  2. Number of treatment-related adverse events assessed by NCI-CTCAE

    Time frame: From the beginning of the nerve block procedure to the end of study visit at 30 days

Secondary outcomes

  1. Pain at rest

    Assessment of pain at rest using the Visual Analog Scale (VAS), 0-10 scale (0 (no pain) to 10 (worst possible pain))

    Time frame: pre-block, and 0, 2, 4, 6, 12, 18, 24 and 48 hours post-block, on Day 15 and 30.

  2. Pain during movement

    Assessment of pain during movement of the surgical site using Visual Analog Scale (VAS), 0-10 scale (0 (no pain) to 10 (worst possible pain))

    Time frame: pre-block, and 0, 2, 4, 6, 12, 18, 24 and 48 hours post-block, on Day 15 and 30

  3. Onset time of motor block

    Onset time of motor block is defined as the time (hour/minutes) from the completion of Ropiclobet injection to the onset of motor block. This will be assessed by grip strength test.

    Time frame: Pre-block, and at 5, 10, 15, 20, 25, 30 minutes, as well as 6, 12, 24 and 48 hours post-injection.

  4. Duration of motor block

    The time of resolution of the motor block (in minutes or hours), assessed by grip strength tests.

    Time frame: From nerve block procedure to the resolution of the motor block, up to 48 hours

  5. Onset time of sensory block

    Onset time of sensory block is defined as the time (hour/minutes) from end of Ropiclobet injection to the onset of sensory block. This will be assessed by cold and touch tests across C5-C8 dermatomes.

    Time frame: Pre-block, and at 5, 10, 15, 20, 25, 30 minutes, as well as 6, 12, 24 and 48 hours post-injection.

  6. Duration of sensory block

    The time of resolution of the sensorial block (in minutes or hours)

    Time frame: From nerve block procedure to the resolution of the sensory block, up to 48 hours

  7. Required rescue analgesia

    Assessment of the frequency of required rescue analgesia intra-operatively.

    Time frame: Perioperative (from nerve block procedure to the end of surgery)

  8. Required rescue analgesia

    Assessment of the frequency of required rescue analgesia postoperatively

    Time frame: From the end of surgery up to 48 hours

  9. Patient satisfaction

    assessment of patient satisfaction using Visual Analog Scale (VAS), 0-10 scale (0=worst, 10=best)

    Time frame: 24 hours following nerve block procedure, and on Day 15 and 30

07

Study locations

1 site
  • Istanbul Medeniyet University, Göztepe Prof. Dr. Süleyman Yalçın City Hospital
    Istanbul, 34722, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Dec 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 20, 2025
StartActual
Sep 2, 2025
Primary completionActual
Dec 3, 2025
CompletionActual
Dec 9, 2025
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07131657
Lead sponsor
PHARMAFINA
Responsible party
Sponsor
First posted
Aug 20, 2025
Start date
Sep 2, 2025
Primary completion
Dec 3, 2025
Completion
Dec 9, 2025
Last update
Jan 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ropivacaine · Clonidine · Betamethasone

Start the discussion